<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72753">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158572</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-CL23</org_study_id>
    <nct_id>NCT02158572</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System</brief_title>
  <official_title>A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the efficacy of a contraceptive patch in 2100 healthy women for up to one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AG200-15 is used in a 4-week (28-day) treatment cycle: a patch is applied and replaced every
      7 days for 3 consecutive weeks, followed by a 1-week &quot;patch-free&quot; period.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contraceptive efficacy of AG200-15</measure>
    <time_frame>Subjects will be treated for up to one year.</time_frame>
    <description>The Pearl Index will serve as the primary contraceptive efficacy endpoint for evaluation of pregnancy rates for the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Pearl Index will serve as the primary contraceptive efficacy endpoint for evaluation of pregnancy rates for the study.</measure>
    <time_frame>one year</time_frame>
    <description>Intent-to-treat (ITT) Efficacy Dataset: All complete or incomplete on-therapy cycles with intercourse and no other birth control methods used.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AG200-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG200-15</intervention_name>
    <description>Transdermal contraceptive delivery system</description>
    <arm_group_label>AG200-15</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, sexually active woman at risk for pregnancy seeking to use hormonal
             contraception for at least 1 year

          -  Ability to demonstrate willingness to participate and adhere to study protocol

        Exclusion Criteria:

          -  Known or suspected pregnancy

          -  Lactating women

          -  Anticipates use of condoms or any other form of back-up contraception during the
             study

          -  History of dermal sensitivity to medicated patches (nicotine) or to bandages,
             surgical tape, etc.

          -  Has a contraindication to combined estrogen-progestin contraceptive use

          -  Any disease that may worsen under hormonal treatment (cardiovascular, liver,
             metabolic)

          -  Smoker who is 35 years old or over
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita L Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Family Health Council</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Kaunitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth I Garner, MD, MPH</last_name>
    <phone>609-356-1927</phone>
    <email>egarner@agiletherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seattle Women's</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-522-3330</phone>
      <phone_ext>02</phone_ext>
      <email>research@seattlewomens.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 2, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention of pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
